During blood coagulation human polymorphonuclear leukocytes release elastase in amounts that can exceed 100 nmol/liter. We therefore studied the effect of elastase on platelet structure and function. Physiologic concentrations of elastase specifically inhibited thrombin-induced platelet aggregation and ristocetininduced agglutination of washed platelets in a time-and dosedependent manner. This was associated with a decrease in the number of high affinity thrombin binding sites on the platelet surface (analysis by "Ligand" program) from 31 per platelet to 12 per platelet (P < 0.05). As analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, treatment of 3H-labeled platelets with elastase resulted in a decrease in the percent glycoprotein at 130,000-150,000 Mr = and an increase in the percent protein at M, = 102,000. The supernatant from elastase-treated platelets contained a Mr = 88,000 glycoprotein not found in the supernatant from untreated platelets. Immunoprecipitation studies with monoclonal antiglycoprotein lb demonstrated that treatment of whole platelets with physiologic concentrations of elastase resulted in proteolytic cleavage of glycoprotein lb. Elastase treatment of glycoprotein immunoisolated with monoclonal antiglycoprotein lb antibody resulted in formation of a glycopeptide with the same electrophoretic mobility as the M, = 102,000 membrane-related glycopeptide.
Introduction
Human polymorphonuclear leukocyte (PMN)' elastase is the major neutral protease released by human PMN during blood coagulation, or activation by soluble immune complexes, C5a, or endotoxin (1) (2) (3) . Elastase is released into the circulation in acute leukemia and in septicemia (4) . Several studies have indicated that the decrease in the concentration of coagulation factors seen in these conditions may be the result of direct proteolysis by leukocyte elastase (5) . Leukocyte elastase also inactivates human antithrombin III (6), a2-plasmin inhibitor, and C1 inactivator (7) . In circulating blood leukocyte elastase is inactivated mainly by a,-antitrypsin (8); however, this inhibitor is readily inactivated by oxidizing agents such as those generated by phagocytosing PMN (9, 10) .
Several studies suggest a potential role for neutrophils in the modulation of hemostasis and thrombosis. Arterial thrombi are characterized by the presence of large numbers of PMN lining the perimeter of platelet aggregates (1 1-13). Marcus et al. (14) and Maclouf et al. (15) have documented that plateletderived arachidonate or 12-hydroperoxy-eicosatetraenoic acid stimulates the biosynthesis of PMN 5,12-dihydroxyeicosatetraenoic acid. This suggests that platelet-derived arachidonate may serve as a precursor for the PMN-derived eicosanoid leukotriene B4, a powerful chemoattractant and secretagogue (15) (16) (17) . Additionally, platelet factor 4, a cationic protein liberated by platelets during the release reaction, has been demonstrated to stimulate PMN elastase activity against elastin (18) (19) (20) .
The present report details studies on the effect of human leukocyte elastase on platelet structure and function. Our findings indicate that physiologic concentrations of elastase specifically inhibit thrombin-induced platelet aggregation and serotonin release as well as ristocetin-induced platelet agglutination. Loss of thrombin responsiveness is accompanied by a reduction in the number of high affinity thrombin binding sites per platelet and by elastase-mediated proteolysis of platelet membrane glycoprotein lb.
Methods
Human PMN elastase. Human PMN elastase was purified from outdated leukocyte concentrates as described (3, 7) . The concentration of elastase was determined by its extinction coefficient of 9.85 (21) . The purified elastase demonstrated one protein-staining band when analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) following reduction with dithiothreitol (DTT) (22) . The specific activity of the elastase was 92% by active site titration using the titrant Ac-Ala-AlaAnval-ONp (a gift of Dr. J. Powers, Georgia Institute of Technology, Atlanta, GA) as described by Powers and Gupton (23) .
previously described and its concentration determined by its extinction coefficient of 5.3 (24) . The final inhibitor preparation was free of other contaminating plasma protease inhibitors as analyzed by double diffusion in agarose gels with specific antibodies against a2-macroglobulin, Cl inactivator, antithrombin-III, inter-a-trypsin inhibitor, or chymotrypsin inhibitor obtained from Calbiochem-Behring Corp., La Jolla, CA.
Platelet aggregation studies. Platelet-rich plasma (PRP) and washed platelet suspensions were prepared by the technique of Mustard et al. (25) as modified by Weksler et al. (26, 27) . Platelet aggregation studies were performed at 370C with 0.4-ml aliquots of PRP or washed platelets (2 X 108/ml) stirred at 1,000 rpm. Platelet aggregation was performed in a Payton 600BD dual-channel aggregometer (Payton Assoc., Scarborough, Ontario, Canada) and recorded with a Soltec 1242 (Sun Valley, CA) dual channel strip chart recorder (28) . Washed platelets (2 X 108/ml) were agglutinated with Ristocetin (Sigma Chemical Co.) 0.5 to 1.0 mg/ml plus VIII:VWF (Hemophil [Hyland Div., Travenol Laboratories, Inc., Costa Mesa, CA]; 0.1 to 0.2 ug/ml).
The threshold stimulus determined for individual platelet preparations was defined as the lowest concentration that caused a 90% or greater increase in light transmission at 5 min when added to stirred platelets at 370C (28) . Elastase inhibition of aggregation by the above agents was tested by adding various concentrations of elastase to platelets for various times at 370C. After inhibiting elastase with alantitrypsin (a,-antitrypsin:elastase molar ratio 5:1), a previously determined threshold dose of the aggregating agent was added, and aggregation was recorded.
Thrombin-induced secretion of["CC]serotonin by platelets. This was measured by standard technique (27, 29) . Before elastase treatment, at least 80% of total ["1C]serotonin was released from platelets upon stimulation with high concentrations of thrombin (>100 nM).
Labeling of"'I-thrombin. a-Thrombin was labeled with 1251 by the method of Martin et al. (30) . Titration of '25I-thrombin with tosylglycyl-L-proline-L-arginine-paranitroanalide (GPA, Vega Fox Biochemicals, Tucson, AZ) was modified from the method of Kirchof et al. (31) . GPA was dissolved in methanol (14 mg/ml) and diluted 10-fold with Tris 0.1 M, CaCl2 1.25 mM, pH 8.3 containing bovine serum albumin I mg/ml (Tris buffer). Serial dilutions of 1251-a-thrombin in Tris buffer (0.15 ml) were mixed with GPA solution. Color development at 405 nm was followed at 10 min intervals in a Titertek Multiscan photometer (Flow Laboratories, Rockville, MD). The change in absorbance per minute in the thrombin-containing wells was subtracted from the values obtained in wells containing no thrombin. The change in absorbance per minute was used to calculate the concentrations of 251-thrombin using a standard curve simultaneously generated by the serial dilution of unlabeled a-thrombin, the concentration of which had been determined by active site titration with p-nitrophenyl-p'-guanidinobenzoate-HCI (32 Platelets (1.5-7 X 108/ml) were equilibrated in this buffer for 10 min at 230C before the addition of thrombin. Incubation with thrombin was for 10 min at 230C unless otherwise specified. Platelets then were separated from buffer (0.3 ml) by layering onto 0.5 ml of a 6.7:3.3 mixture of Dow 550 (Dow Chemical Co., Midland, MI) and Dow 556 silicone oil (sp gr 1.040; Dexter Corp., Olean, NY) (33) and by centrifugation in a 1.5-ml conical polypropylene centrifuge tube (12,000 g for 2 min) in an Eppendorf centrifuge. Two 0. l-ml aliquots of the aqueous phase were transferred to counting vials. The tube was carefully inverted, drained, and the bottom of the tube containing the platelet pellet was sheared from the tube and counted in a Searle 1185 gamma counter (Searle Radiographics, Inc., Des Plaines, IL). The maximum binding of thrombin to platelets was reached within 5 min after addition of thrombin; binding remained maximum for at least 30 min after addition of thrombin. Of added [ (34) . The Ligand program was used to correct for nonspecific binding using both a one-site and two-site model.
'H-Labeling of platelet surface glycoproteins. Platelet surface glycoproteins were labeled with tritium by modification of established methods (35, 36) . Washed platelets from 150 ml of whole blood were resuspended at 0C in 1.3 ml of 137 mM NaCl, 2.7 mM KCI, 1.2 mM NaHCO3, 0.4 mM NaH2PO4, I mM MgC12, 2 mM CaC12, 0.1% glucose, 0.35% bovine serum albumin, pH 7.35. Sodium metaperiodate (2 mM) 0.15 ml was added to the platelet suspension prior to incubating in the dark for 10 min at 0°C. The suspension was diluted with buffer, sedimented by centrifugation at 1,067 g for 10 min and washed once more. The platelets resuspended in 1.5 ml buffer at 23°C were mixed with 2.5 mCi [3H]NaBH4 (New England Nuclear, Boston, MA) in 0.01 ml NaOH (0.01 M). After 30 min, cold buffer (25 ml) was added and the platelets centrifuged at 1,067 g for 10 min. The platelets were resuspended, and centrifuged twice more. Aliquots were taken for study by aggregometry as detailed above.
Treatment of 'H-labeled platelets with elastase. The 3H-labeled platelet suspensions (2 X 109 platelets/ml) were exposed to either elastase (0-300 nM) or (39) . After electroblotting, the nitrocellulose was incubated overnight at 4°C in phosphate-buffered saline (PBS, 100 mM NaCl, 38 mM Na2HPO4, 12.5 mM NaH2PO4, pH 7.4) containing 5% bovine serum albumin (Sigma Chemical Co., essentially fatty acid free) and 3 mM NaN3.
The nitrocellulose was incubated an additional 30 min in PBS containing 0.5% (vol/vol) Tween 20 (PBS-Tween), and the blocked nitrocellulose membrane then was incubated with primary antibody (rabbit antihuman glycoprotein Ilb or lIla) (40) diluted 1:100 in PBS-Tween for I h at 370C with gentle rocking. The membrane was washed three times with PBS-Tween and incubated with biotinylated goat antirabbit IgG (Enzo Biochem, New York) diluted 1:1000 in PBS-Tween for I h at 370C with gentle rocking. The membrane was washed three times with PBS-Tween, rinsed once in PBS, and incubated 30 min at 230C in PBS containing 5 mM trisodium EDTA, 2% bovine serum albumin, and 0.05% (vol/vol) Triton X-100. Avidin-acid phosphatase complex (Enzo Biochem) diluted 1:200 in PBS, 5 mM trisodium EDTA was incubated with the membrane (0.08 ml/cm2) for I h at 230C before washing 5 times for 5 min each in 10 mM K2HPO4, 0.5 M NaCl, 1 mM EDTA, pH 6.5, containing 2% bovine serum albumin and 0.5% Triton X-100. The membrane was rinsed twice (2 min per rinse) in a clean dish with 0.2 M acetic acid, 0.2 M sodium acetate, pH 5.8. To detect the complex the membrane was incubated 5 min with 1 mM Naphthol AS-MX phosphate (Enzo Biochem), 0.2 M sodium acetate, pH 5.8, before adding 1/100 vol of Fast violet B salt (Enzo Biochem) 4 mg/ml in 0.2 M sodium acetate, pH 5.8. Color development at 23°C was first observed after 5-20 min. After 1 to 4 h, the membrane was removed from the dye solution, rinsed in tapwater, and air dried. The color of the bands on some nitrocellulose membranes faded upon drying. The addition of water or buffer (neutral or slightly acidic) restored color.
Immunoprecipitation ofplatelet membrane proteins. This was modified from the techniques of Kessler (41) and Coller et al. (42) . Washed platelets were prepared from 150 ml freshly drawn blood and radiolabeled with [3H]NaBH4 as detailed above. The platelets (1.4 X 10'0/ml) were divided into two 0.7-ml portions and treated with elastase (80 nM) or buffer for 3 min at 370C. a,-Antitrypsin (0.2 uM) was added and the samples centrifuged at 12,000 g for 30 s.
The precipitates were resuspended in 1.0 ml PBS, pH 7.4, containing 1% Triton X-100, 1 mM leupeptin (Sigma Chemical Co.) and 3 mM NaN3 at 4°C for 15 min with sonication (three times for 15-20 s, power reading 3.5 with a 41/2-in. microprobe and microsonicator, Kontes Glass Co., Vineland, NJ). The samples were centrifuged at 5,000 g for 15 min at 4°C, and the supernatant recentrifuged at 40,000 g for 1 h at 4°C.
Immunobeads (1.0 ml) coated with rabbit anti-mouse immunoglobulin (10 mg/ml, Bio-Rad Laboratories, Richmond, CA) were washed three times in PBS containing 0.5% Triton X-100, 0.02% NaN3, 0.1% bovine serum albumin, pH 8.4 (PBS-Triton), by spinning at 1,500 g for 2 min and resuspending in 1.0 ml after each wash. The beads were divided into two 0.5-ml portions and mixed with 1.0 ml of either normal mouse ascites fluid (Cappel Laboratories, Cochranville, PA) diluted 1:1000 in PBS-Tween or dessicated ascites fluid containing monoclonal antiglycoprotein lb (AP-1, a generous gift of Thomas Kunicki; Blood Center of Southeastern Wisconsin) (43) reconstituted in PBS containing 1 mg/ml BSA, and then similarly diluted 1:1000 in PBS-Tween.
After incubating for 40 min at 23°C and 10 min at 37°C, samples were washed four times in PBS-Triton and resuspended in 0.5 ml buffer. The solubilized platelet proteins (0.1 ml) and the antibody coated Immunobeads (0.1 ml) were incubated 60 h at 4°C with mixing and centrifuged 12,000 g for 2 min. The pellet was washed three times in PBS-Triton as above. To release the bound antigen, the pellet was mixed with 0.1 ml of a solution consisting of one part 3.3% SDS, 6 mM N-ethylmaleimide, and one part 1% SDS, 12.5 mM Tris-HCI, 20% glycerol, 0.025% Bromphenol blue, pH 6.8, and heated to 100°C for 3 min. Samples were centrifuged at 12,000 g for 2 min and the supernatants stored (-70°C). Samples (10,000 dpm/lane) were analyzed by electrophoresis as described above.
Immunoisolation of platelet membrane glycoprotein lb was modified from the technique of McEver et al. (44) . Immunobeads were coated with monoclonal antiglycoprotein lb as detailed above. Solubilized 3H-labeled platelet membrane proteins (0.5 ml), prepared as above, and antibody coated Immunobeads (0.5 ml) were incubated 60 h at 4°C with mixing and centrifuged at 12,000 g for 2 min. The Immunobeads were washed three times in PBS-Triton before washing in 0.15 M finally in 0.15 M NaCl, 0.02 M Tris-HCI, 1% Triton X-100, pH 7.4.
Bound protein was eluted with 0.05 M diethylamine, 1% Triton X-100, pH 11.5. The eluate was neutralized with 2 M Tris-HCI, 1% Triton X-100, pH 7.4, dialyzed against 0.15 M NaCl, 0.02 M TrisHCl, 2.5 mM EDTA, and stored at 4VC. Aliquots were incubated with either elastase (5 nM) or buffer for various times at 370C prior to heating (1000C) for 3 min with an equal volume of 0.06 M Tris-HCI, 2% SDS, 5% glycerol, 0.001% bromphenol blue, and 2% DTT. All samples were stored (-70'C) prior to electrophoresis (10,000 dpm/lane).
Results
Elastase inhibition of thrombin-induced platelet aggregation.
Elastase inhibited thrombin-induced platelet aggregation in a time-and dose-dependent manner. In Fig. 1 , washed platelets (2 X 108/ml) were stirred with either elastase (10 nM; 30,000 molecules/platelet) or with buffer for 1 min at 37°C. A threshold dose of thrombin (1 nM) then was added. The elastase-treated platelets failed to aggregate, whereas the buffertreated platelets responded normally. The concentration of elastase chosen was below that documented to appear during blood coagulation (28-140 nM) (3). Although aggregation of elastase-treated platelets did not occur after exposure to thrombin, examination by phase microscopy revealed that shape change had occurred. In subsequent experiments, the inhibition of thrombin-induced platelet aggregation was found to be both time and dose dependent (Fig. 2) . Elastase inhibition of ristocetin-mediated agglutination paralleled the inhibition of thrombin stimulation. In contrast, similar concentrations of elastase did not inhibit platelet aggregation by ADP, epinephrine, arachidonic acid, or collagen.
To explore whether the action of elastase was due either to a direct interaction with platelets or to proteolytic inactivation of thrombin, a,-antitrypsin was used to inhibit elastase activity.
In Fig. 3 (bottom) elastase (10 nM) was incubated with washed platelets for 1 min at 37°C. After inhibition of elastase by addition of a,-antitrypsin (64 nM), thrombin (1 nM) was added. Aggregation did not occur. These experiments suggested that elastase inhibited aggregation by acting on the platelet rather than on thrombin. In a separate study (Fig. 3, top tracing) a,-antitrypsin (64 nM) was added to washed platelets prior to addition of elastase. Elastase was then added and the mixture incubated for 1 min (37°C). Subsequent addition of thrombin (1 nM) resulted in aggregation. This study demon- (Fig. 5) . The Scatchard plot of thrombin binding before elastase treatment (Fig. 5, closed circles) (Fig. 6 ) and densitometry. In comparison with untreated platelets (Fig. 6 a) , there was a marked difference in platelet surface membrane glycoproteins after treatment with elastase ( Fig. 6 b) . First, elastase treatment resulted in a decrease in the relative percentage of glycoprotein in the range of Mr = 130,000 to 150,000. Proteins in this range include glycoproteins lb and IIb (47) . Concomitant with this was a relative increase in glycoprotein at Mr = 102,000. The supernatants from both elastase-treated and untreated platelets were similarly analyzed. Untreated platelets (Fig. 6 c) showed one band at Mr = 131,000 believed to be glycocalicin (47) . Compared with control platelets the supernatant from the elastase-treated platelets (Fig. 6 d) showed new protein bands at approximate molecular weights of 88,000, 35,000, and 29,000. Protein at Mr = 88,000 is in the region of glyco- protein V (48, 49) . However, the quantity of protein at this molecular weight raises the possibility that at least part of the protein was formed by elastase cleavage of a higher molecular weight glycoprotein precursor.
To explore further the action of elastase on platelet surface glycoproteins, 3H-label6d platelets (10'0/ml) were incubated with elastase (50 nM; 3,000 molecules elastase/platelet), a 16-fold lesser concentration than used in Fig. 6 . As demonstrated in Fig. 7 (lanes 1-5) The supernatants from platelets after elastase treatment were similarly analyzed (Fig. 7, lanes 6-10) . The supernatants prior to elastase treatment showed a single band at Mr = 131,000 believed to be glycocalicin as in Fig. 6 . Within 30/s of incubation with elastase, protein at Mr = 131,000 is reduced, and a new band appears at Mr = 35,000. With longer incubation times, protein is observed at -Mr = 88,000, migrating ahead of the Mr = 102,000 band observed in lanes 1-5. At 60 min a faint band at Mr = 29,000 appears.
In experiments not shown, incubation of platelets with elastase in the presence of EDTA (I mM) or antipain (0.2 mM) gave similar results, suggesting that calcium activated protease was not an essential component of this interaction (50) .
Immunoenzymatic analysis of the effect of elastase on glycoproteins JIb and lIIa. The effects of elastase on platelet glycoproteins IIb and MIIa were analyzed by Western blot technique followed by immunoenzymatic detection of the glycoprotein with avidin-acid phosphatase complex (Fig. 8) . The treatment of platelets with concentrations of elastase sufficient to inhibit thrombin-induced platelet aggregation did not alter the molecular weight or the apparent quantity of platelet glycoproteins IIb and IlIa. Glycoprotein IIb is detected at Mr = 136,000 (Fig. 8 a) . Treatment of platelets with elastase does not alter its molecular weight (Fig. 8 b) . Likewise, glycoprotein IIIa is apparent at Mr = 106,000 both before and after elastase treatment (Fig. 8 c, d ). The lighter band at Mr = 122,000 in Fig. 8 c, d is in the position that glycoprotein IIIa is found after reduction. Similar analysis of samples after reduction with dithiothreitol confirmed that treatment of platelets with elastase did not alter the electrophoretic mobility of glycoproteins Ilb and Ila (data not shown).
Immunoprecipitation Approximately 23% of the radioactivity from solubilized platelet membranes not pretreated with elastase bound to the AP-1 coated beads. In contrast, after elastase treatment of washed platelets, 0.9% of the radioactivity from the solubilized platelet membrane bound to the AP-1 coated beads. Control beads coated with normal mouse IgG bound less than 0.5% of total radioactivity both before and after elastase treatment.
The immunoprecipitate formed by the AP-l antibody with 3H-labeled platelet membranes was analyzed by polyacrylamide gel electrophoresis (10,000 dpm/lane) after solubilization in SDS. As shown by fluorography, the control bead immunoprecipitate from either solubilized normal platelets (Fig. 9 c or solubilized elastase-treated platelets (Fig. 9 a) moved with the buffer front. In contrast, the AP-I immunoprecipitate from untreated platelets (Fig. 9 d) (42) was not observed. After treatment with elastase ( Fig. 9 b) , the relative intensity of the bands at Mr 167,000 and 130,000 was reduced. Concomitant with this was the appearance of a protein band at Mr -35,000, corresponding to the M, = 35,000 band found in the supernatant of elastase-treated platelets. That this peptide contains the antigenic site for the AP-1 monoclonal antibody and is not merely adhering nonspecifically to the AP-1 coated beads remains to be proven. These studies demonstrate that treatment of whole platelets with elastase results in the degradation of glycoprotein lb.
Effect of elastase on glycoprotein Ib. Platelet membrane glycoprotein was immunopurified with Immunobeads coated with the AP-I anti-glycoprotein lb antibody. Human leukocyte elastase (5 nM) was incubated with immunopurified, 3H-labeled glycoprotein and the mixtures were analyzed by SDS-PAGE after reduction with dithiothreitol. As shown by fluorography (Fig. 10) , the molecular weight of the glycoprotein immunoisolate prior to elastase treatment was -140,000. Upon incubation with elastase for 0.5 min, the relative intensity of the band at 140,000 was reduced and a new band appeared at Mr 94,000. After one min, most of the radioactivity was found in the Mr -94,000 band. No additional degradation was observed with incubation for up to 60 min (Fig. 10, lanes a-e). In the control experiment (Fig. 10, lanesf-j) , incubation of the immunoisolate in the absence of elastase did not result in the formation of a lower molecular weight peptide.
These experiments demonstrated that elastase-mediated proteolysis of the Mr = 140,000 glycoprotein resulted in the formation of a Mr -94,000 cleavage product. On SDS-PAGE Figure 10 . Effect of elastase on platelet glycoprotein lb. Glycoprotein lb was immunoprecipitated and eluted as described in Methods. The isolated glycoprotein was incubated for various times with 5 nM elastase (lanes a-e) or with buffer (lanesf-j) at 37°C prior to heating at 100°C for 3 min with an equal volume of 0.06 M Tris-HCI, 2% SDS, 5% glycerol, 0.001% Bromphenol blue, and 2% DTT. After electrophoresis in a 9% polyacrylamide gel, fluorograms were obtained by exposure of the gel to the film for 7 d. this peptide comigrated with the Mr -102,000 glycopeptide found in elastase-treated platelets (Fig. 6 d) , and it migrated more slowly than the Mr = 88,000 glycopeptide appearing in the supernatant of elastase-treated platelets (gel not shown). These findings suggested that elastase-mediated proteolysis of membrane-bound glycoprotein lb resulted in formation of a Mr = 94,000 to 102,000 membrane-associated glycopeptide (Figs. 6, 7, and 10) .
Glycoprotein V has a molecular weight of 68,000 to 85,000 (48, 49) , raising the possibility that a portion of the Mr = 88,000 glycopeptide appearing in the supernatant of elastasetreated platelets is glyoprotein V. However, immunoprecipitation studies similar to those above using anti-glycoprotein V antibody (the kind gift of Dr. David Phillips, Gladstone Foundation Laboratories, San Francisco, CA) (54), demonstrated that elastase treatment did not increase the concentration of glycoprotein V in platelet supernatants (data not shown).
Discussion
These studies demonstrate that physiologic concentrations of human leukocyte elastase inhibit thrombin-induced platelet aggregation in a time-and dose-dependent manner. Leukocyte elastase also inhibits ristocetin-induced platelet agglutination and the release of ['4C]serotonin from platelets. This loss of functional activity is associated with (a) a reduction in the number of high affinity thrombin binding sites per platelet and (b) the proteolysis of platelet glycoprotein lb.
The low concentration of elastase used to demonstrate inhibition of thrombin-induced platelet aggregation in this study indicates that platelets are highly susceptible to elastase and suggests that these findings are of physiologic relevance. As blood coagulates, polymorphonuclear leukocytes degranulate and release elastase (2, 3) . Several potentially toxic reactive oxygen species also can be released by degranulated leukocytes (55) . a,-Antitrypsin, the major plasma inhibitor of elastase, is particularly susceptible to oxidants that can react with the methionine at the reactive center of the inhibitor, thus inactivating its protease-inhibiting activity (10) . In a cell contact system Campbell et al. (56) demonstrated that a,-antitrypsin inhibited about 80% of PMN-derived proteolytic activity. Although PMN-derived oxidants did not potentiate elastasemediated proteolysis in this system, Weiss and Regiani (57) showed that concentrations of ac-antitrypsin less than 250 Jg/ ml can be inhibited by a PMN-mediated H202-dependent mechanism. Additionally, Matheson et al. (58) demonstrated that oxidation of a,-antitrypsin by myeloperoxidase is optimized at acidic pH (6.2) such as might be found in an area of thrombosis or inflammation. Conditions present during coagulation might thus facilitate the elastase-mediated proteolysis of platelets as detailed in this study.
The interaction of physiologic concentrations of elastase with platelets is rapid. At an elastase concentration of 50 nM (3,000 elastase molecules/platelet), major quantities of glycoproteins lb were degraded within 60 s. This correlates with functional studies detailing loss of thrombin responsiveness within this time interval when similar elastase concentrations are used. The finding that glycoprotein lb is affected by elastase treatment remains compatible with the hypothesis that thrombin might interact with glycoprotein lb (59) (60) (61) (62) .
Elastase treatment of glycoprotein immunopurified with antiglycoprotein Ib antibody produced a peptide with the same electrophoretic mobility as the Mr -102,000 glycopeptide on the surface of elastase-treated platelets, suggesting that it is a glycoprotein lb fragment. However, the origin of the M, = 88,000 protein in the supernatant of elastase-treated platelets remains unknown. The difference in the molecular weights of these two peptides is similar to that between the a-chain of glycoprotein lb Mr = 143,000) (51, 52) and glycocalicin (Mr = 135,000) (47, 53) . This raises the possibility that the Mr = 88,000 peptide might result from elastase-mediated cleavage of glycocalicin. Proof of this hypothesis requires further experimental studies.
As previously reported (30, (63) (64) (65) , analysis of thrombinplatelet binding kinetics demonstrates both high and low affinity thrombin binding sites. The number of low affinity binding sites and the Kd reported in this study (4,600±5,100 sites/platelet, Kd = 98±90 nM) is compatible with the findings of the above authors. However, using computer analysis we have found both the number of high affinity sites per platelet (31 ±10) and the Kd (0.10±0.06) to be less than the values previously published (290 to 1,500 sites/platelet; Kd = 0.2 to 3.2 nM). We attribute these differences strictly to a more accurate resolution of kinetic constants by the Ligand program for fitting multiple binding site data (34) , which was not available to the above investigators. (In studies not shown, analysis using the technique of Chamness and McGuire (66) revealed two classes of binding sites, 340 sites with a Kd of -1.6 nM and 14,000 sites with a Kd of =-180 nM, values similar to those reported for the high and low affinity sites.) It appears then that accurate resolution of kinetic constants for the high affinity thrombin receptor by linear regression and extrapolation of the Scatchard plot results in a 10-fold higher value compared to mathematical resolution of the same data using the Ligand program.
A criterion for defining "specific" binding of thrombin to platelets is that it is correlated with physiologic effects (30) . Both platelet secretion and platelet aggregation occur at thrombin concentration of 0.1 to I nM (Figs. I and 4) . From thiembin binding studies (Fig. 5) it can be calculated that this range of concentrations encompasses the steep portion of the thrombin binding curve. (An added thrombin concentration of about I nM corresponds approximately to a bound/free ratio of 0.10 and to a bound thrombin concentration of 0.1 nM. At a platelet concentration of 2 X 109/ml, this is equivalent to 30 molecules thrombin/platelet). Approximately 30 thrombin molecules binding per platelet will thus maximize platelet secretion. This suggests that the high affinity sites also are the specific receptors for both the aggregation and secretion reactions. As noted by others (30) it remains possible that the binding of additional thrombin molecules per platelet may produce other as yet unidentified effects on the platelet.
